-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IBI-322 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IBI-322 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. IBI-322 in Solid Tumor Drug Details: IBI-322 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Patidistrogene Bexoparvovec in Limb-Girdle Muscular Dystrophy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Patidistrogene Bexoparvovec in Limb-Girdle Muscular Dystrophy report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Patidistrogene Bexoparvovec in Limb-Girdle Muscular DystrophyDrug Details:patidistrogene bexoparvovec (SRP-9004) is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Vutiglabridin in Parkinson’s Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Vutiglabridin in Parkinson's Disease report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Vutiglabridin in Parkinson's Disease Drug Details: HSG-4112 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CT-38 in Fibromyalgia (Fibromyalgia Syndrome)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.CT-38 in Fibromyalgia (Fibromyalgia Syndrome) Drug Details:CT-38 is under development for the treatment of chronic fatigue...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – KB-0742 in Epithelial Ovarian Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - KB-0742 in Epithelial Ovarian Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. KB-0742 in Epithelial Ovarian Cancer Drug Details: KB-0742 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Abemaciclib in Metastatic Colorectal Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Abemaciclib in Metastatic Colorectal Cancer Drug Details: Abemaciclib (Verzenio / Verzenios / Yulareb) is a...
-
Product Insights
Plus Power/ SRP – Gilbert Superstition 90-MW – Arizona
Equip yourself with the essential tools needed to make informed and profitable decisions with our Plus Power/ SRP - Gilbert Superstition 90-MW - Arizona report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive deep into...
-
Product Insights
Plus Power/ SRP – Avondale Sierra Estrella 250 MW – Arizona
Equip yourself with the essential tools needed to make informed and profitable decisions with our Plus Power/ SRP - Avondale Sierra Estrella 250 MW - Arizona report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive...
-
Product Insights
NextEra Energy/ SRP – Valley Farms Solar 200 MW – Arizona
Equip yourself with the essential tools needed to make informed and profitable decisions with our NextEra Energy/ SRP - Valley Farms Solar 200 MW - Arizona report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive...
-
Product Insights
SRP – Coolidge Gas Fired Generating Station 820 MW – Arizona
Equip yourself with the essential tools needed to make informed and profitable decisions with our SRP - Coolidge Gas Fired Generating Station 820 MW - Arizona report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive...